• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

GHX Acquires Lumere to Advance Clinically Integrated Supply Chains

by Jasmine Pennic 01/13/2020 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

GHX Acquires Lumere to Advance Clinically Integrated Supply Chains

– Global Healthcare Exchange (GHX) announced it has acquired Chicago-based Lumere, a provider of evidence-based data and analytics solutions that enable healthcare organizations to build clinically integrated supply chains and optimize medication formulary management. 

– As reimbursement models move from fee-for-service to fee-for-value, GHX believes Lumere’s capabilities will extend its value to more directly improve patient outcomes at the lowest cost by empowering customers to make evidence-based purchasing and utilization decisions. 

Global Healthcare Exchange (GHX) today announced it has acquired Chicago-based Lumere, a provider of evidence-based data and analytics solutions that enable healthcare organizations to build clinically integrated supply chains and optimize medication formulary management. Financial terms of the deal were not disclosed. Key Lumere leaders, including CEO Hani Elias, CTO Will Danford and President/Chief Strategy Officer Eric Meizlish will remain with the combined organization.

Driving Healthcare’s Clinically Integrated Supply Chains

Founded in 2012, Lumere (formerly Procured Health) is an organization comprised of clinicians, researchers, software engineers and strategic advisors focused on helping health systems eliminate unwarranted clinical variation and cut unnecessary costs—specifically related to device and drug selection and utilization. By providing both physicians and hospital leaders with evidence-based data, information and analytics they’ve previously lacked, Lumere accelerates their ability to optimize patient care and decrease healthcare’s financial burden.

Lumere has emerged as the industry-leading source of technology solutions that drive evidence-based device and drug utilization and purchasing decisions. Spend on medical products and drugs represents one of the fastest-growing expenses for US health systems. The combination of Lumere’s capabilities with GHX’s unmatched network of providers and suppliers will enable the industry standard for device and drug intelligence needed to optimize patient value.

“Together, GHX and Lumere will provide an unmatched source of information that enables health systems to align purchasing and utilization decisions with evidence,” added Hani Elias, CEO at Lumere. “Our combined companies will help healthcare stakeholders deliver care that’s backed by data and guided by evidence, allowing drug and device expenditures to be supported not just by price but by clinical outcomes. Shining a light on outcomes will provide clinicians and hospital administrators with the information they need to help make the best decisions for every patient. I’m incredibly excited about the significant change our two companies can advance for healthcare.”

Acquisition Creates A Gold Standard for Device & Drug Intelligence to Optimize Patient Value

As reimbursement models move from fee-for-service to fee-for-value, GHX believes Lumere’s capabilities will extend its value to more directly improve patient outcomes at the lowest cost by empowering customers to make evidence-based purchasing and utilization decisions. Since its founding, GHX has created healthcare’s largest vendor-neutral modern digital trading network with access to hospitals representing more than 80% of licensed beds and a significant number of major suppliers in the US.

By combining the powerful assets of GHX and Lumere, GHX seeks to create the gold standard in data governance, providing a single source of trusted information for the management of devices and drugs used in the delivery of care. The Lumere acquisition also significantly extends GHX’s footprint in the pharmaceutical market, helping health systems more strategically manage the complex area of pharmacy cost.

“With health systems more accountable than ever for the results they deliver, the strategic imperatives of reducing cost and improving quality of care are more critical than ever,” said Bruce Johnson, CEO and president of GHX. “We’ll continue to support our customers in their evolution from reimbursement based on quantity to reimbursement based on quality. We will do this by combining the strength of the GHX platform and the industry’s most comprehensive repository of item and transaction data, with Lumere’s deep clinical data and machine learning powered analyticsto deliver the critical evidence-based insights healthcare needs. Like GHX, Lumere is a company focused on innovation and customer-centricity, and we couldn’t be more delighted to welcome them into our organization.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Data Governance, GHX, GHX Healthcare, global healthcare, Health Systems, Healthcare Mergers & Acquisitions, Healthcare Supply Chain, Hospital Supply Chain, Machine Learning, Medical Supply Chain, medication, Patient Care, Pharmacy, physicians

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

The AI Paradox in Healthcare: Notable CEO Shares Why Moving Too Slowly is a Greater Risk

Most-Read

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

KLAS Report: Epic's Native Ambient Speech Tool Reshapes Customer AI Strategies

KLAS Report: Epic’s Native Ambient Speech Tool Reshapes Customer AI Strategies

Epic Unveils MyChart Central and New APIs to Advance Interoperability at Open@Epic

Epic Outlines Roadmap for Next-Generation Data Sharing at Open@Epic

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

Oracle Confirms Layoffs in Kansas City

Oracle Confirms Layoffs in Kansas City

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Optain Health Secures $26M to Advance AI-Powered Retinal Screening

Optain Health Secures $26M for AI-Powered Retinal Screening

Sutter Health and Epic Launch "Sutter Sync" to Optimize Remote Chronic Care

Sutter Health and Epic Launch “Sutter Sync” to Optimize Remote Chronic Care

Patient Square Capital Acquires Premier in $2.6B Deal

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |